Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation

Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination

“…Similar observations for the RNA processing factor THRAP3 upon DNA damage have been reported (Beli et al 2012). HDACs are recruited to damage sites and are involved in the DDR (Miller et al 2010;Gong and Miller 2013). Thus, histone deacetylation could signal the disassembly of BRD proteins by removing their requisite chromatin-binding site.…”

“…S2C). As a control, we depleted the HAT MOF, which targets histone H4 and is involved in the DDR (Sharma et al 2010;Gong and Miller 2013). Depletion of MOF, unlike TIP60, did not reduce ZMYND8 recruitment to DNA damage (Supplemental Fig.…”

High-resolution mapping of H4K16 and H3K23 acetylation reveals conserved and unique distribution patterns inArabidopsisand rice

“…[4][5][6][7] Histone acetylation homeostasis plays a vital role in a diverse array of biological processes, including DNA replication, DNA repair, gene silencing, genome defense, genome organization, normal growth and development, physiology, aging, and numerous diseases. [8][9][10][11][12][13] In plants, recent advances in high throughput sequencing technology have enabled the large-scale profiling of histone acetylation marks and have greatly improved our understanding of the function of histone acetylation and its relationship with transcription. [14][15][16][17][18] Besides its role in gene expression, plant histone acetylation plays crucial roles in the crosstalk between genomes and the environment during plant responses to diverse stresses at the cellular and organismal levels.…”

Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor

“…12,13) Previous studies have found that in a variety of cancers, HDACs have abnormal activity and expression. 12) And epigenome-targeting drug vorinostat (also known as suberoylanilide hydroxamic acid) is a direct HDAC inhibitor that has been approved for clinical trials of various cancers, such as T cell lymphomas.…”